Dr Parikh on the Feasibility and Importance of Immunotherapy Trials in Anal Cancer

“PODIUM-303, and...other [key studies] have shown us that...these trials are feasible and are a tremendous unmet need [in SCAC]."

Aparna R. Parikh, MD, an assistant in medicine, Hematology and Oncology, and attending oncologist for the Tucker Gosnell Center for Gastrointestinal Cancers and Henri and Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital; as well as an associate professor of medicine at Harvard Medical School, discussed the importance of conducting immunotherapy trials in squamous cell anal carcinoma (SCAC).

Globally, approximately 50,000 cases of anal cancer are reported annually, a figure that Parikh suggested may be underreported in certain regions. Despite the rarity of the disease, which represents only 1% to 6% of anorectal tumors, Parikh emphasized that recent research efforts are successfully reshaping the treatment paradigm in both the metastatic and early-stage settings. Historically, there has been significant skepticism and reluctance from the pharmaceutical industry regarding the feasibility of clinical trials in such a rare population. However, she noted that landmark studies such as the phase 3 POD1UM-303/InterAACT 2 (NCT04472429) trial have demonstrated that these trials are not only feasible but essential for addressing a profound unmet need in this space

Parikh also highlighted the evolving landscape of drug development for HPV-linked malignancies, expressing interest in how the incidence of SCAC may shift over time following the broader adoption of HPV vaccination. Furthermore, she noted a vital shift in drug development and trial eligibility for patients living with HIV. Though they have historically been excluded from many studies in SCAC, patients with well-controlled viral loads are now increasingly permitted to enroll in clinical trials, representing a more inclusive and realistic approach to research in this population, she asserted. Ultimately, Parikh asserted that the success of trials like PODIUM-303 and various SWOG cooperative group efforts should encourage the industry to continue driving research in rare cancers. By prioritizing these underserved populations and adapting trial designs to be more inclusive, the SCAC community can continue to uncover new biological insights and improve the standard of care, Parikh concluded.